ClinicalTrials.Veeva

Menu
The trial is taking place at:
M

Monroe Research, LLC | West Monroe, LA

Veeva-enabled site

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (POWER-HF)

Akros Pharma logo

Akros Pharma

Status and phase

Enrolling
Phase 2

Conditions

Chronic Heart Failure

Treatments

Drug: JTT-861 Capsules
Drug: Placebo Capsules

Study type

Interventional

Funder types

Industry

Identifiers

NCT06017609
AT861-G-22-002

Details and patient eligibility

About

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

Enrollment

300 estimated patients

Sex

All

Ages

30 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has a clinical diagnosis of symptomatic heart failure (HF) ≥90 days prior to the Screening Visit;
  • Is in New York Heart Association (NYHA) functional class II or III at the Screening Visit;
  • Is on stable, guideline-directed therapy for HF, consistent with American Heart Association (AHA), American College of Cardiology (ACC), Heart Failure Society of America (HFSA) or European Society of Cardiology (ESC) guidelines for ≥4 weeks prior to the Screening Visit (with at least half of maximal labeled dose of renin-angiotensin-aldosterone system (RAAS) inhibitors and β-blockers, if tolerated);
  • Has left ventricular ejection fraction (LVEF) ≤35% at the Screening Visit;
  • Has a serum N-terminal pro b-type natriuretic peptide (NT-pro-BNP) level ≥600 pg/mL (or ≥900 pg/mL if the subject has atrial fibrillation or atrial flutter) at the Screening Visit.

Exclusion criteria

  • Has a confirmed acute myocardial infarction (MI) (i.e., Type 1) or unstable angina within 90 days prior to the Screening Visit;
  • Has a history of coronary revascularization (percutaneous coronary intervention [PCI] and/or coronary artery bypass graft [CABG]) or other cardiovascular surgery within 90 days prior to the Screening Visit or planned cardiovascular surgery during the study through the Follow-up Visit);
  • Has started cardiac resynchronization therapy (CRT) within 90 days prior to the Screening Visit or has planned CRT during the study through the Follow-up Visit;
  • Has clinically significant congenital heart disease, active myocarditis or constrictive pericarditis;
  • Has current acute decompensated HF requiring additional treatment with diuretics, vasodilators and/or inotropic medications at the Screening Visit;
  • Has clinically significant chronic renal insufficiency (i.e., estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation) at the Screening Visit.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

300 participants in 3 patient groups

JTT-861 Dose 1
Experimental group
Description:
JTT-861 Capsules Dose 1 orally once daily for 12 weeks
Treatment:
Drug: JTT-861 Capsules
JTT-861 Dose 2
Experimental group
Description:
JTT-861 Capsules Dose 2 orally once daily for 12 weeks
Treatment:
Drug: JTT-861 Capsules
Placebo
Experimental group
Description:
Placebo Capsules orally once daily for 12 weeks
Treatment:
Drug: Placebo Capsules

Trial contacts and locations

19

Loading...

Central trial contact

Kala Patel, R.Ph., RAC; Takanori Nemoto, M.S.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems